These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 30835732

  • 1. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [Abstract] [Full Text] [Related]

  • 2. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.
    Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [Abstract] [Full Text] [Related]

  • 3. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE.
    JAMA Oncol; 2021 Jan 01; 7(1):42-50. PubMed ID: 33180106
    [Abstract] [Full Text] [Related]

  • 4. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D.
    Cancer Med; 2019 May 01; 8(5):2041-2055. PubMed ID: 30950237
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.
    Franke GN, Maier J, Wildenberger K, Cross M, Giles FJ, Müller MC, Hochhaus A, Niederwieser D, Lange T.
    J Mol Diagn; 2020 Jan 01; 22(1):81-89. PubMed ID: 31669230
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH, Li H, Cai H.
    Leuk Res; 2017 Aug 01; 59():8-11. PubMed ID: 28527402
    [Abstract] [Full Text] [Related]

  • 8. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM, Watkins DB, Hughes TP, Branford S.
    Clin Chem; 2008 Sep 01; 54(9):1568-71. PubMed ID: 18641042
    [Abstract] [Full Text] [Related]

  • 9. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.
    Cancer; 2017 Jul 01; 123(13):2482-2488. PubMed ID: 28241101
    [Abstract] [Full Text] [Related]

  • 10. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R, Press RD.
    Leuk Lymphoma; 2017 Jan 01; 58(1):8-16. PubMed ID: 27412040
    [Abstract] [Full Text] [Related]

  • 11. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
    Tantiworawit A, Kongjarern S, Rattarittamrong E, Lekawanvijit S, Bumroongkit K, Boonma N, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Norasetthada L.
    Asian Pac J Cancer Prev; 2016 Jan 01; 17(4):2159-64. PubMed ID: 27221912
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.
    Haematologica; 2018 Jan 01; 103(1):107-115. PubMed ID: 29079599
    [Abstract] [Full Text] [Related]

  • 13. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
    Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, Carne L, Rwodzi Z, Watts S, McLean J, Braley J, Altamura H, Yeung DT, Branford S, Yong ASM, White DL, Hughes TP, Ross DM.
    Leukemia; 2020 Apr 01; 34(4):1052-1061. PubMed ID: 31768016
    [Abstract] [Full Text] [Related]

  • 14. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S.
    Acta Clin Belg; 2015 Aug 01; 70(4):237-43. PubMed ID: 26166681
    [Abstract] [Full Text] [Related]

  • 15. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ, Zheng CF, Liu Z, Tan YH, Chen XH, Zhao BL, Li GX, Xu ZF, Ren FG, Zhang YF, Chang JM, Wang HW.
    Eur J Haematol; 2018 Sep 01; 101(3):291-296. PubMed ID: 29691899
    [Abstract] [Full Text] [Related]

  • 16. Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
    Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F.
    Int J Mol Sci; 2019 May 06; 20(9):. PubMed ID: 31064152
    [Abstract] [Full Text] [Related]

  • 17. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 18. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR, Rempfer CB, Press RD.
    Methods Mol Biol; 2013 Sep 05; 999():1-23. PubMed ID: 23666687
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.
    Int J Clin Oncol; 2017 Oct 05; 22(5):972-979. PubMed ID: 28550414
    [Abstract] [Full Text] [Related]

  • 20. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
    Moumen A, Dehbi H, Kottwitz D, El Amrani M, Bouchoutrouch N, El Hadi H, Quessar A, Benchekroun S, Nadifi S, Sefrioui H.
    Genet Mol Res; 2015 Feb 06; 14(1):1044-55. PubMed ID: 25730044
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.